Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
An overview of the top 10 stories from Optometry Times in 2025.
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Bowie, professor in the department of ophthalmology at ...
Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...
According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback